Bright Minds Biosciences ... (DRUG)
Bright Minds Biosciences Inc. (DRUG) Stock Price, Analysis & Data
No data available
| Bid | 78.65 |
| Market Cap | 750.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.35M |
| Beta | 0.09 |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.82 |
| P/B (ttm) | 3.38 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2026 |
| Ask | 80.03 |
| Volume | 147,082 |
| Avg. Volume (20D) | 312,461 |
| Open | 77.03 |
| Previous Close | 78.00 |
| Day's Range | 75.28 - 77.98 |
| 52-Week Range | 38.00 - 123.75 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathi...
Financial Performance
In 2025, Bright Minds Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -12.23M, an increase of 336.46%.
Financial StatementsAnalyst Forecast
According to undefined analyst ratings, the average rating for DRUG stock is "undefined". The 12-month stock price forecast is null, which is downside of 0% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
